Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience

BACKGROUND: In resource-constrained areas, generic direct-acting antivirals (DAAs) have considerably reduced the cost of hepatitis C virus (HCV) therapy while there remain significant costs related to the baseline and follow-up virologic assays. AIM: The aim was to assess the efficacy and safety of...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Exp Hepatol
Главные авторы: Bwa, Aung H., Nangia, Gayatri, Win, Si T.S., Maung, Soe T., Han, Khin A.W., Htar, Su S., Wine, Lei Y., Ko, Wint W., Oo, Moe P., Hlaing, Naomi K.T., Palecki, Julia, Loza, Bao L., Win, Khin M., Reddy, Rajender
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2019
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6637231/
https://ncbi.nlm.nih.gov/pubmed/31360020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2018.12.001
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы